Track GlaxoSmithKline plc — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

GlaxoSmithKline plc GSK · Stock Open GlaxoSmithKline plc in new tab

51.97 USD
Add to portfolio
P/E
13.28
EPS
3.82
Yield
3.45%
Safety Score
92
P/B
4.28
ROE
40.91
Beta
0.30
Target Price
58.08 USD
GlaxoSmithKline plc logo

GlaxoSmithKline plc

🧾 Earnings Recap – Q3 2025

GSK's Q3 2025 results reflect robust growth with total sales increasing by 8%, driven by strong performance in specialty medicines, and a significant upgrade in guidance for the year. The company also reported positive cash generation and progress in R&D, highlighting its commitment to innovation and sustainability.

  • Total sales reached GBP 8.5 billion in Q3, up 8% year-over-year, with specialty medicines growing 16%.
  • Core operating profit increased by 11%, and core EPS rose 14% to 55p.
  • GSK secured four FDA approvals this year, including for BLENREP, and expects to launch a low-carbon version of Ventolin in 2026.
  • Cash generation stood at GBP 6.3 billion year-to-date, supporting ongoing investments and a quarterly dividend of 16p.
  • Full-year specialty guidance has been upgraded from low teens to mid-teens percentage growth.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJuly 28, 2026
P/E13.28
EPS3.82
Book Value11.85
Price to Book4.28
Debt/Equity109.70
% Insiders0.060%
Growth
Revenue Growth0.02%
Earnings Growth0.08%
Estimates
Forward P/E9.83
Forward EPS5.16
Target Mean Price58.08
Dividend
Dividend Yield3.45%
Annual dividends1.34 USD
Ex-Div. DateMay 15, 2026
Payout44.52%
5y avg Yield4.77%

DCF Valuation

Tweak assumptions to recompute fair value for GlaxoSmithKline plc (GSK)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

GlaxoSmithKline plc Logo GlaxoSmithKline plc Analysis (GSK)

United Kingdom Health Care Official Website Stock

Is GlaxoSmithKline plc a good investment? GlaxoSmithKline plc (GSK) is currently trading at 51.97 USD. Market analysts have a consensus price target of 58.08 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 13.28. This relatively low multiple may signal that GlaxoSmithKline plc is undervalued compared to historical market norms.

Earnings Schedule: GlaxoSmithKline plc is expected to release its next earnings report on July 28, 2026. The market consensus estimate for Forward EPS is 5.16.

For income investors, GlaxoSmithKline plc pays a dividend yield of 3.45%. With a payout ratio of 45%, the dividend appears sustainable.

Investor FAQ

Does GlaxoSmithKline plc pay a dividend?

Yes, it pays an annual dividend of 1.34 USD (3.45% yield).

What asset class is GlaxoSmithKline plc?

GlaxoSmithKline plc is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be July 28, 2026. The company currently has a trailing EPS of 3.82.

Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.

Exchange Ticker
NYQ (United States) GSK
Trades
Dividend Yield
3.45%
5y avg 4.77%
Annual Dividends
1.34USD
Next Ex. Div Date
May 15, 2026
Payout Ratio
44.52%
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2027
0.85 USD
April 8, 2027 (estimated) 0.4592
Jan. 14, 2027 (estimated) 0.3907
▸2026
1.77 USD
Oct. 8, 2026 (estimated) 0.4076
July 9, 2026 0.4610
April 9, 2026 0.4860
Jan. 8, 2026 0.4170
▸2025
1.65 USD
Oct. 9, 2025 0.4280
July 10, 2025 0.4290
April 10, 2025 0.4010
Jan. 9, 2025 0.3890
▸2024
1.51 USD
Oct. 10, 2024 0.3860
July 11, 2024 0.3760
April 11, 2024 0.4060
Jan. 11, 2024 0.3400
▸2023
1.37 USD
Oct. 12, 2023 0.3610
July 13, 2023 0.3480
April 13, 2023 0.3400
Jan. 12, 2023 0.3170
▸2022
1.89 USD
Oct. 6, 2022 0.3910
July 1, 2022 0.3500
April 7, 2022 0.6220
Jan. 13, 2022 0.5230
▸2021
2.18 USD
Oct. 7, 2021 0.5300
July 8, 2021 0.5270
April 8, 2021 0.6280
Jan. 14, 2021 0.4960
▸2020
2.05 USD
Oct. 8, 2020 0.4910
July 9, 2020 0.4720
April 9, 2020 0.5990
Jan. 9, 2020 0.4890
▸2019
2.05 USD
Oct. 10, 2019 0.4640
July 11, 2019 0.4950
April 11, 2019 0.5970
Jan. 10, 2019 0.4910
▸2018
2.17 USD
Oct. 11, 2018 0.5010
July 12, 2018 0.5300
April 12, 2018 0.6380
Jan. 11, 2018 0.5040
▸2017
2.02 USD
Oct. 12, 2017 0.4960
July 13, 2017 0.4880
April 13, 2017 0.5760
Jan. 12, 2017 0.4640
▸2016
2.89 USD
Oct. 13, 2016 0.4990
July 14, 2016 0.5540
April 14, 2016 1.2520
Jan. 14, 2016 0.5820
▸2015
2.48 USD
Oct. 1, 2015 0.5930
July 9, 2015 0.5770
April 9, 2015 0.6950
Jan. 8, 2015 0.6130
▸2014
2.65 USD
Oct. 2, 2014 0.6480
July 10, 2014 0.6400
April 10, 2014 0.7500
Jan. 9, 2014 0.6160
▸2013
2.37 USD
Oct. 3, 2013 0.5530
July 11, 2013 0.5500
April 11, 2013 0.6890
Jan. 3, 2013 0.5790
▸2012
2.44 USD
Oct. 4, 2012 0.5280
July 5, 2012 0.5490
April 12, 2012 0.8210
Jan. 5, 2012 0.5430
▸2011
2.17 USD
Oct. 6, 2011 0.5210
July 7, 2011 0.5260
April 7, 2011 0.6150
Jan. 6, 2011 0.5070
▸2010
1.98 USD
Oct. 7, 2010 0.4570
July 8, 2010 0.4600
April 8, 2010 0.5740
Jan. 7, 2010 0.4900
▸2009
1.84 USD
Oct. 8, 2009 0.4610
July 9, 2009 0.4090
April 9, 2009 0.4950
Jan. 8, 2009 0.4750
▸2008
2.20 USD
Oct. 9, 2008 0.5190
July 10, 2008 0.5190
April 10, 2008 0.6270
Jan. 10, 2008 0.5330
▸2007
1.98 USD
Oct. 11, 2007 0.4950
July 12, 2007 0.4810
April 12, 2007 0.5520
Jan. 4, 2007 0.4510
▸2006
1.64 USD
Oct. 5, 2006 0.4060
July 6, 2006 0.3930
April 6, 2006 0.4880
Jan. 5, 2006 0.3550
▸2005
1.54 USD
Oct. 6, 2005 0.3480
July 7, 2005 0.3800
April 7, 2005 0.4440
Jan. 6, 2005 0.3650
▸2004
1.54 USD
Sept. 30, 2004 0.3660
July 1, 2004 0.3530
April 15, 2004 0.5200
Jan. 6, 2004 0.3000
▸2003
1.38 USD
Oct. 2, 2003 0.2860
July 3, 2003 0.3170
April 17, 2003 0.4650
Jan. 3, 2003 0.3080
▸2002
1.87 USD
Oct. 3, 2002 0.3110
July 5, 2002 0.5550
April 18, 2002 0.7150
Jan. 3, 2002 0.2840
▸2001
1.31 USD
Oct. 4, 2001 0.2830
July 5, 2001 0.2870
April 27, 2001 0.7420
▸2000
1.29 USD
Oct. 26, 2000 0.5020
June 5, 2000 0.7850
▸1999
1.13 USD
Oct. 12, 1999 0.5390
June 1, 1999 0.5950
▸1998
1.15 USD
Oct. 13, 1998 0.4960
June 1, 1998 0.6520
▸1997
1.22 USD
Dec. 2, 1997 0.4910
May 30, 1997 0.7270
▸1996
1.16 USD
Oct. 11, 1996 0.5840
May 30, 1996 0.5800
▸1995
1.16 USD
Nov. 2, 1995 0.7740
April 20, 1995 0.3850
▸1994
1.03 USD
Sept. 23, 1994 0.6950
March 14, 1994 0.3320
▸1993
0.36 USD
Sept. 24, 1993 0.0580
March 5, 1993 0.3050
▸1992
0.86 USD
Sept. 21, 1992 0.5800
Feb. 28, 1992 0.2810
▸1991
0.57 USD
Sept. 16, 1991 0.3835
March 15, 1991 0.1825
▸1990
0.47 USD
Sept. 24, 1990 0.3170
March 30, 1990 0.1510
▸1989
0.32 USD
Oct. 5, 1989 0.2235
April 7, 1989 0.0945
▸1988
0.13 USD
Nov. 18, 1988 0.0610
April 18, 1988 0.0735
▸1987
0.18 USD
Nov. 20, 1987 0.1420
May 15, 1987 0.0420
▸1986
0.45 USD
Nov. 21, 1986 0.3295
May 8, 1986 0.1216
▸1985
1.24 USD
Nov. 22, 1985 0.9227
May 9, 1985 0.3217
▸1984
0.45 USD
Nov. 26, 1984 0.4520
Upcoming Dividends
Name Payment Date Status Amount
GlaxoSmithKline plc Jul 09, 2026 0.461 USD
GlaxoSmithKline plc Apr 09, 2026 0.486 USD
GlaxoSmithKline plc Jan 08, 2026 0.417 USD
GlaxoSmithKline plc Oct 09, 2025 0.428 USD
Stock Splits
Split Date Split Ratio to 1
Feb. 22, 1983 2.000000
Jan. 27, 1986 2.000000
Nov. 12, 1991 2.000000
July 22, 2022 1.230000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion